These lines of evidence highlight the role of CD73 in shaping suppressive immune microenvironment specific to EGFR mutations, which may explain in part, the limited responsiveness to immunotherapy in EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.